Summit Therapeutics Inc. will showcase updated Phase III data for its investigational bispecific antibody, ivonescimab, at the 2026 European Lung Cancer Congress (ELCC) in Copenhagen, Denmark. The company’s three posters will be displayed on March 27, 2026, from 1:00 to 2:00 pm Central European Time, marking the first public disclosure of additional efficacy data for ivonescimab, Summit’s sole product candidate in development for non‑small cell lung cancer.
The data presented will highlight intracranial progression‑free survival (PFS) improvements in patients with brain metastases, with a median PFS of 10.1 months versus 6.5 months observed in the HARMONi study. This intracranial benefit is a critical unmet need in EGFR‑mutated NSCLC and positions ivonescimab as a potential competitor to established immunotherapies such as pembrolizumab, especially for patients who have progressed on EGFR tyrosine‑kinase inhibitors.
Summit’s regulatory strategy is reinforced by the presentation. The company has submitted a Biologics License Application (BLA) to the FDA, with a PDUFA goal action date of November 14, 2026, and the drug holds Fast Track designation. Ivonescimab is already approved in China (May 2024) and is being developed in collaboration with Akeso Inc., with 15 Phase III trials underway across multiple tumor types, including colorectal, biliary tract, and head‑and‑neck cancers.
The ELCC presentation is expected to accelerate regulatory momentum and strengthen Summit’s competitive positioning in the EGFR‑mutated NSCLC market. By demonstrating intracranial efficacy and aligning with a near‑term PDUFA date, Summit signals confidence in the drug’s clinical value and its potential to address a significant unmet need for patients with brain metastases, thereby enhancing investor interest and supporting the company’s long‑term growth strategy.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.